South African medicines with clinical-trial evidence for a new indication
18 of the 395 medicines with a ZaTxGNN report have a TxGNN-predicted new indication graded at evidence level L1 or L2 (5 at L1, 13 at L2), meaning clinical-trial evidence (randomised trials, Phase 2–3 trials or systematic reviews) was found for it.
The medicines come from the South African Medicine Price Registry, with SAHPRA registration status shown in each drug report, and the list below reflects the drug reports as last updated on 2026-11-03.
Trial evidence for a predicted indication is not proof of efficacy. Every candidate below still requires clinical validation and regulatory review before any clinical use.
Medicines with trial evidence (L1–L2)
| Drug | Predicted new indication | Evidence level | Registered trials cited (NCT) |
|---|---|---|---|
| Candesartan | Migraine disorder | L1 (with caveat) | 4 |
| Clomipramine | Anxiety disorder | L1 | 9 |
| Montelukast | Bronchitis | L1 (with caveat) | 10 |
| Potassium | Hypertensive disorder | L1 (with caveat) | 7 |
| Tacrolimus | Seborrheic dermatitis | L1 (with caveat) | 4 |
| Atorvastatin | HIV infectious disease | L2 | 14 |
| Bupropion | attention deficit-hyperactivity disorder | L2 | 6 |
| Citalopram | Obsessive-compulsive disorder | L2 (with caveat) | 4 |
| Clonazepam | restless legs syndrome | L2 | 0 |
| Docetaxel | Ewing sarcoma | L2 | 8 |
| Hydrocortisone | alopecia areata | L2 | 1 |
| Hydrocortisone Acetate | Alopecia areata | L2 (with caveat) | 1 |
| Midazolam | Insomnia (disease) | L2 (with caveat) | 2 |
| Moclobemide | Agoraphobia | L2 | 0 |
| Mycophenolate Mofetil | HIV infectious disease | L2 (with caveat) | 4 |
| Pravastatin | HIV infectious disease | L2 | 12 |
| Prednisolone | Alopecia areata | L2 | 0 |
| Prednisone | Alopecia areata | L2 | 0 |
How to read this list
- Evidence level follows the methodology: L1 = multiple Phase 3 RCTs or systematic reviews; L2 = a single RCT or multiple Phase 2 trials. “(with caveat)” means the drug report qualifies the grade; read the note in the report before relying on it.
- Predicted new indication is the main prediction shown in each drug report. Indications and contraindications already recorded in the TxGNN knowledge graph are excluded, so some predictions may still overlap an established use; the report explains this where it applies.
- Registered trials cited counts the ClinicalTrials.gov (NCT) numbers cited in the drug report. Reports cite a selection of the trials found; 0 means the report cites no registered trial, and its literature evidence section shows the basis for the grade.
- For all levels, see High Evidence (L1-L2) and All Drugs.
Disclaimer
This report is for academic research reference only and does not constitute medical advice. Always follow your physician's instructions; never adjust medication on your own. Any drug repurposing decision requires full clinical validation and regulatory review.
Reviewed by: 藥提醒科技有限公司 (yao.care)
This report is for academic research reference only and does not constitute medical advice. Always follow your physician's instructions; never adjust medication on your own. Any drug repurposing decision requires full clinical validation and regulatory review.
Reviewed by: 藥提醒科技有限公司 (yao.care)